Elicera Therapeutics AB Cash Flow Reinvestment Rate
Latest as of December 2023:
0.00x
Elicera Therapeutics AB cash flow reinvestment rate. Elicera Therapeutics AB (ELIC) has a Cash Flow Reinvestment Rate of 0.00x as of December 2023, reinvesting Skr2.00K (capex Skr1.00K plus investments Skr-1.00K) from operating cash flow of Skr3.50 Million. Explore how well can Elicera Therapeutics AB service its debt to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
0.00x
(Capex + Investments) / Operating CF
Total Reinvested
Skr2.00K
Capex + Investments
Operating Cash Flow
Skr3.50 Million
SEK
Capital Expenditures
Skr1.00K
SEK
Elicera Therapeutics AB Cash Flow Reinvestment Rate by Year (None–None)
Elicera Therapeutics AB cash flow reinvestment rate by year from None to None. Year-by-year capital reinvestment analysis for Elicera Therapeutics AB. For the full cash flow conversion analysis, see cash efficiency ratio of Elicera Therapeutics AB.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow